A citation-based method for searching scientific literature

Magda Bahcall, Mark M Awad, Lynette M Sholl, Frederick H Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V Ivanova, Giulia C Leonardi, Bryan C Ulrich, Cloud P Paweletz, Paul T Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J Nagy, Richard B Lanman, Marzia Capelletti, Emily S Chambers, Amanda J Redig, Paul A VanderLaan, Daniel B Costa, Yu Imamura, Pasi A Jänne. Clin Cancer Res 2018
Times Cited: 31







List of co-cited articles
306 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
363
61

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Ken Suzawa, Michael Offin, Daniel Lu, Christopher Kurzatkowski, Morana Vojnic, Roger S Smith, Joshua K Sabari, Huichun Tai, Marissa Mattar, Inna Khodos,[...]. Clin Cancer Res 2019
45
58

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
309
54

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
393
54

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Rebecca S Heist, Lecia V Sequist, Darrell Borger, Justin F Gainor, Ronald S Arellano, Long P Le, Dora Dias-Santagata, Jeffrey W Clark, Jeffrey A Engelman, Alice T Shaw,[...]. J Thorac Oncol 2016
86
48

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Lars D Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A Tovar, Curt J Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P Lopez-Casas,[...]. Clin Cancer Res 2017
61
45

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Sai-Hong Ignatius Ou, Lauren Young, Alexa B Schrock, Adrienne Johnson, Samuel J Klempner, Viola W Zhu, Vincent A Miller, Siraj M Ali. J Thorac Oncol 2017
67
41

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Toshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, Takamasa Koga, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Kenji Tomizawa, Toshiki Takemoto,[...]. J Thorac Oncol 2019
35
41

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
Magda Bahcall, Taebo Sim, Cloud P Paweletz, Jyoti D Patel, Ryan S Alden, Yanan Kuang, Adrian G Sacher, Nam Doo Kim, Christine A Lydon, Mark M Awad,[...]. Cancer Discov 2016
79
38

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Joanna H Tong, Sai F Yeung, Anthony W H Chan, Lau Y Chung, Shuk L Chau, Raymond Wai Ming Lung, Carol Y Tong, Chit Chow, Edith K Y Tin, Yau H Yu,[...]. Clin Cancer Res 2016
194
38

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
96
38


Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu,[...]. Cancer Res 2006
324
35

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Xuewen Liu, Yuxia Jia, Mark B Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balazs Halmos, Alain C Borczuk. J Clin Oncol 2016
190
35

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
104
35

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Patrick C Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, Maria S Tretiakova, Vidya Nallasura, Edward A Fox, Mark Hansen, Erik Schaefer, Katsuhiko Naoki, Alan Lader,[...]. Cancer Res 2005
440
32

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Alexa B Schrock, Garrett M Frampton, James Suh, Zachary R Chalmers, Mark Rosenzweig, Rachel L Erlich, Balazs Halmos, Jonathan Goldman, Patrick Forde, Kurt Leuenberger,[...]. J Thorac Oncol 2016
158
32

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
32


Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Eun Kyung Kim, Kyung A Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim. Clin Lung Cancer 2019
32
29

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis,[...]. Clin Cancer Res 2019
56
29

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
David R Spigel, Martin J Edelman, Kenneth O'Byrne, Luis Paz-Ares, Simonetta Mocci, See Phan, David S Shames, Dustin Smith, Wei Yu, Virginia E Paton,[...]. J Clin Oncol 2017
149
29

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
Federico Cappuzzo, Antonio Marchetti, Margaret Skokan, Elisa Rossi, Sujatha Gajapathy, Lara Felicioni, Maela Del Grammastro, Maria Grazia Sciarrotta, Fiamma Buttitta, Matteo Incarbone,[...]. J Clin Oncol 2009
422
25

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
25

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Alexa B Schrock, Andrea Lai, Siraj M Ali, Vincent A Miller, Luis E Raez. J Thorac Oncol 2017
24
33

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Julia K Rotow, Philippe Gui, Wei Wu, Victoria M Raymond, Richard B Lanman, Frederic J Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B Corcoran,[...]. Clin Cancer Res 2020
24
33

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
38
25


Targeting MET in cancer: rationale and progress.
Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier, George Vande Woude. Nat Rev Cancer 2012
986
22

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.
Xinyuan Lu, Nir Peled, John Greer, Wei Wu, Peter Choi, Alice H Berger, Sergio Wong, Kuang-Yu Jen, Youngho Seo, Byron Hann,[...]. Cancer Res 2017
35
22

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Ryoichi Onozato, Takayuki Kosaka, Hiroyuki Kuwano, Yoshitaka Sekido, Yasushi Yatabe, Tetsuya Mitsudomi. J Thorac Oncol 2009
207
22

Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.
Hua-Jie Dong, Peng Li, Chang-Ling Wu, Xiao-Yue Zhou, Hong-Jun Lu, Tong Zhou. Lung Cancer 2016
32
22

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
22

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.
Samuel J Klempner, Ali Borghei, Behrooz Hakimian, Siraj M Ali, Sai-Hong Ignatius Ou. J Thorac Oncol 2017
43
22

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T DiMare, Hyo-Eun Carrie Bhang, Youzhen Wang,[...]. Clin Cancer Res 2019
48
22

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
232
22

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge. J Thorac Oncol 2017
160
19

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Ralph Tiedt, Elisa Degenkolbe, Pascal Furet, Brent A Appleton, Sabrina Wagner, Joseph Schoepfer, Emily Buck, David A Ruddy, John E Monahan, Michael D Jones,[...]. Cancer Res 2011
87
19

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Anna Li, Jin-Ji Yang, Xu-Chao Zhang, Zhou Zhang, Jian Su, Lan-Ying Gou, Yu Bai, Qing Zhou, Zhenfan Yang, Han Han-Zhang,[...]. Clin Cancer Res 2017
45
19

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
P Peschard, T M Fournier, L Lamorte, M A Naujokas, H Band, W Y Langdon, M Park. Mol Cell 2001
307
19

Molecular cloning of a new transforming gene from a chemically transformed human cell line.
C S Cooper, M Park, D G Blair, M A Tainsky, K Huebner, C M Croce, G F Vande Woude. Nature 1984
852
19

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
19

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo. Lung Cancer 2018
36
19

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Patrick C Ma, Takashi Kijima, Gautam Maulik, Edward A Fox, Martin Sattler, James D Griffin, Bruce E Johnson, Ravi Salgia. Cancer Res 2003
366
19

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Wei Jin, Benjie Shan, Hu Liu, Shoubing Zhou, Wenjuan Li, Jing Pan, Lin Lin, Dandan Hu, Yueyin Pan. J Thorac Oncol 2019
14
42

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Samantha X Y Wang, Bing M Zhang, Heather A Wakelee, Michael Z Koontz, MingGui Pan, Maximilian Diehn, Christian A Kunder, Joel W Neal. Anticancer Drugs 2019
18
33

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Mark M Awad, Giulia C Leonardi, Sasha Kravets, Suzanne E Dahlberg, Alexander Drilon, Sinead A Noonan, D Ross Camidge, Sai-Hong I Ou, Daniel B Costa, Shirish M Gadgeel,[...]. Lung Cancer 2019
37
19

EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Friedhelm Bladt, Bettina Faden, Manja Friese-Hamim, Christine Knuehl, Claudia Wilm, Claus Fittschen, Ulrich Grädler, Michael Meyring, Dieter Dorsch, Frank Jaehrling,[...]. Clin Cancer Res 2013
68
19

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko,[...]. Lancet Oncol 2017
150
19

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
83
19


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.